Portal de Periódicos da CAPES

Administration of Neomycin Resistance Gene Marked EBV Specific Cytotoxic T Lymphocytes to Recipients of Mismatched-Related or Phenotypically Similar Unrelated Donor Marrow Grafts. St. Jude Children's Research Hospital, Memphis, Tennesse

1994; Mary Ann Liebert, Inc.; Volume: 5; Issue: 3 Linguagem: Inglês

10.1089/hum.1994.5.3-381

1557-7422

Helen E. Heslop, Malcolm K. Brenner, Cliona M. Rooney, Robert A. Krance, William Roberts, Richard Rochester, Colton A. Smith, Victoria Turner, John W. Sixbey, Robert C. Moen, James M. Boyett,

Herpesvirus Infections and Treatments

Human Gene TherapyVol. 5, No. 3 News and CommentsAdministration of Neomycin Resistance Gene Marked EBV Specific Cytotoxic T Lymphocytes to Recipients of Mismatched-Related or Phenotypically Similar Unrelated Donor Marrow Grafts. St. Jude Children's Research Hospital, Memphis, TennessePRINCIPAL INVESTIGATORS Helen E. Heslop, Malcolm K. Brenner, Cliona Rooney, CO-INVESTIGATORS Robert A. Krance, W. Mark Roberts, Richard Rochester, Colton A. Smith, Victoria Turner, John Sixbey, Robert Moen, and James M. BoyettPRINCIPAL INVESTIGATORS Helen E. HeslopSearch for more papers by this author, Malcolm K. BrennerSearch for more papers by this author, Cliona RooneySearch for more papers by this author, CO-INVESTIGATORS Robert A. KranceSearch for more papers by this author, W. Mark RobertsSearch for more papers by this author, Richard RochesterSearch for more papers by this author, Colton A. SmithSearch for more papers by this author, Victoria TurnerSearch for more papers by this author, John SixbeySearch for more papers by this author, Robert MoenSearch for more papers by this author, and James M. BoyettSearch for more papers by this authorPublished Online:19 Mar 2008https://doi.org/10.1089/hum.1994.5.3-381AboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail FiguresReferencesRelatedDetailsCited byCancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects3 March 2022 | Frontiers in Immunology, Vol. 13The Tumor Microenvironment in Post-Transplant Lymphoproliferative Disorders24 January 2019 | Cancer Microenvironment, Vol. 12, No. 1Characterization of PD-L1 and PD-1 Expression and CD8+ Tumor-infiltrating Lymphocyte in Epstein-Barr Virus-associated Nasopharyngeal CarcinomaAmerican Journal of Clinical Oncology, Vol. 41, No. 12The doubling potential of T lymphocytes allows clinical-grade production of a bank of genetically modified monoclonal T-cell populationsCytotherapy, Vol. 20, No. 3Specific Adoptive T-Cell Therapy for Viral and Fungal Infections19 June 2018Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non‐Hodgkin lymphoma7 April 2016 | British Journal of Haematology, Vol. 173, No. 4Targeting Cytomegalovirus-Infected Cells Using T Cells Armed with Anti-CD3 × Anti-CMV Bispecific AntibodyBiology of Blood and Marrow Transplantation, Vol. 18, No. 7Exploiting the Interplay between Innate and Adaptive Immunity to Improve Immunotherapeutic Strategies for Epstein-Barr-Virus-Driven DisordersClinical and Developmental Immunology, Vol. 2012NCI First International Workshop on the Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: Report from the Committee on Prevention of Relapse Following Allogeneic Cell Transplantation for Hematologic MalignanciesBiology of Blood and Marrow Transplantation, Vol. 16, No. 8Accelerated Production of Antigen-specific T Cells for Preclinical and Clinical Applications Using Gas-permeable Rapid Expansion Cultureware (G-Rex)Journal of Immunotherapy, Vol. 33, No. 3Treatment of lymphoma with adoptively transferred T cells2 September 2009 | Expert Opinion on Biological Therapy, Vol. 9, No. 11The prevention and treatment of cytomegalovirus infection in haematopoietic stem cell transplantation23 May 2009 | Cancer Immunology, Immunotherapy, Vol. 58, No. 9Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I–II studyThe Lancet Oncology, Vol. 10, No. 5Donor Lymphocyte Infusions Clinical Applications and the Graft‐versus‐Leukemia EffectLymphoproliférations après transplantationEMC - Hématologie, Vol. 1, No. 1In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation1 July 2009 | Leukemia & Lymphoma, Vol. 47, No. 5Musculoskeletal Gene Therapy and its Potential Use in the Treatment of Complicated Musculoskeletal InfectionInfectious Disease Clinics of North America, Vol. 19, No. 4Graft Manipulation to Prevent Graft-vs.-Host Disease9 April 2013Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignanciesTissue Antigens, Vol. 63, No. 4Vaccines in LeukemiaDonor Lymphocyte InfusionsThe Generation and Characterization of LMP2-Specific CTLs for Use as Adoptive Transfer From Patients With Relapsed EBV-Positive Hodgkin DiseaseJournal of Immunotherapy, Vol. 27, No. 4T‐Cell Depletion to Prevent Graft‐vs.‐Host Disease26 October 2007Resolution of oral non-Hodgkin's lymphoma by reduction of immunosuppressive therapy in a renal allograft recipient: A case report and review of the literatureOral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology, Vol. 94, No. 6Cellular immunotherapy for viral infections in solid organ transplant recipientsCurrent Opinion in Organ Transplantation, Vol. 7, No. 4Epstein–Barr virus and post‐transplant lymphoproliferative disease9 December 2002 | Pediatric Transplantation, Vol. 6, No. 6Cellular therapy for haematological malignancies18 November 2002 | Vox Sanguinis, Vol. 83, No. 4Adapting a transforming growth factor β–related tumor protection strategy to enhance antitumor immunityBlood, Vol. 99, No. 9Generation of EBV‐specific CTLs suitable for adoptive immunotherapy of EBV‐associated lymphoproliferative disease following allogeneic transplantation20 June 2002 | APMIS, Vol. 110, No. 2Immunotherapy to reconstitute immunity to DNA virusesSeminars in Hematology, Vol. 39, No. 1The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantationBlood, Vol. 98, No. 12Virus epstein-barr et système immunitaireRevue Française des Laboratoires, Vol. 2001, No. 337Purification of Ag-Specific T Lymphocytes After Direct Peripheral Blood Mononuclear Cell Stimulation Followed by CD25 Selection. I. Application to CD4+ or CD8+ Cytomegalovirus Phosphoprotein pp65 Epitope DeterminationThe Journal of Immunology, Vol. 167, No. 8An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLsBlood, Vol. 97, No. 4Adoptive Immunotherapy of EBV-Associated Malignancies with EBV-Specific Cytotoxic T-Cell LinesEX VIVO GENERATION OF EFFECTIVE EPSTEIN-BARR VIRUS (EBV)-SPECIFIC CD8+ CYTOTOXIC T LYMPHOCYTES FROM THE PERIPHERAL BLOOD OF IMMUNOCOMPETENT EPSTEIN BARR VIRUS-SERONEGATIVE INDIVIDUALS1Transplantation, Vol. 70, No. 10Posttransplantation Lymphoproliferative Disorder in Children: Clinical, Histopathologic, and Imaging FeaturesRadiology, Vol. 217, No. 1The T Cell Repertoire Selected In Vitro Against EBV: Diversity, Specificity, and Improved Purification Through Early IL-2 Receptor α-Chain (CD25)-Positive Selection1 May 2000 | The Journal of Immunology, Vol. 164, No. 9CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantationBlood, Vol. 95, No. 4Genetic Modulation of Effector Cells to Enhance GVL Effects16 January 2010Adoptive Transfer of Polyclonal, EBV-Specific Cytotoxic T-Cell Lines for the Prevention and Treatment of EBV-Associated MalignanciesActivation and adoptive transfer of Epstein–Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease31 August 1999 | Proceedings of the National Academy of Sciences, Vol. 96, No. 18A γ-herpesvirus sneaks through a CD8 + T cell response primed to a lytic-phase epitope3 August 1999 | Proceedings of the National Academy of Sciences, Vol. 96, No. 16CD4 + T cell-mediated control of a γ-herpesvirus in B cell-deficient mice is mediated by IFN-γ27 April 1999 | Proceedings of the National Academy of Sciences, Vol. 96, No. 9Cytokine mRNA profiles in Epstein–Barr virus‐associated post‐transplant lymphoproliferative disorders23 May 2002 | Clinical Transplantation, Vol. 13, No. 1Transfer of EBV-specific CTL to prevent EBV lymphoma post bone marrow transplantJournal of Clinical Apheresis, Vol. 14, No. 3Prevention of EBV‐induced B‐lymphoproliferative disorder by ex vivo marrow B‐cell depletion in HLA‐phenoidentical or non‐identical T‐depleted bone marrow transplantation4 January 2002 | British Journal of Haematology, Vol. 103, No. 2Infusion of Cytotoxic T Cells for the Prevention and Treatment of Epstein-Barr Virus–Induced Lymphoma in Allogeneic Transplant RecipientsBlood, Vol. 92, No. 5Feasibility of Cellular Adoptive Immunotherapy for Epstein-Barr Virus-Associated Lymphomas Using Haploidentical Donors RIMAS J. ORENTAS, M. VICTOR LEMAS, MIRIAM J. MULLIN, PAUL M. COLOMBANI, KATHLEEN SCHWARZ, and RICHARD AMBINDER27 March 2009 | Journal of Hematotherapy, Vol. 7, No. 3Immunotherapy for Epstein-Barr Virus-Associated CancersJNCI Monographs, Vol. 1998, No. 23T Lymphocyte Based HIV Gene Therapy StrategiesGene Therapy for Infectious DiseasesClinical Microbiology Reviews, Vol. 11, No. 1AIDS-related malignancies8 July 2009 | Annals of Medicine, Vol. 30, No. 4Cord Blood Mononuclear Cell Transformation Assay for Screening for the Presence of Epstein-Barr Virus KENNETH G. LUCAS, ROBERT BURTON, DOUGLAS K. HEILMAN, KAREN POLLOK, and DAVID EMANUEL27 March 2009 | Journal of Hematotherapy, Vol. 6, No. 6Virus-Specific Cytotoxic T Lymphocytes as Prophylaxis for Epstein-Barr Virus Lymphoproliferative Disease in Pediatric Bone Marrow Transplant Recipients1 January 1997 | Journal of Pediatric Oncology Nursing, Vol. 14, No. 4Outcomes of transplantation with matched-sibling and unrelateddonor bone marrow in children with leukaemiaThe Lancet, Vol. 350, No. 9080Gene therapy and blood cell transplantationSeminars in Oncology Nursing, Vol. 13, No. 3Adoptive cellular immunotherapy for EBV lymphoproliferative diseases9 October 2008 | Immunological Reviews, Vol. 157, No. 1Control of virus-induced lymphoproliferation: Epstein-Barr virus-induced lymphoproliferation and host immunityMolecular Medicine Today, Vol. 3, No. 1Gene Marking Malcolm Brenner20 March 2008 | Human Gene Therapy, Vol. 7, No. 16DIAGNOSIS AND MANAGEMENT OF SYSTEMIC NON-HODGKIN'S LYMPHOMA IN HIV DISEASEHematology/Oncology Clinics of North America, Vol. 10, No. 5Long–term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene–modified virus–specific T lymphocytes1 May 1996 | Nature Medicine, Vol. 2, No. 5Gene Transfer into Hemopoietic Progenitors: Implications for Bone Marrow TransplantationAdoptive Immunotherapy for Epstein-Barr Virus-Related Lymphoma1 July 2009 | Leukemia & Lymphoma, Vol. 23, No. 3-4Bone Marrow and Clinical Gene Therapy GABRIELE D. SCHMIDT-WOLF and INGO G.H. SCHMIDT-WOLF27 March 2009 | Journal of Hematotherapy, Vol. 4, No. 6Gene-marking and haemopoietic stem-cell transplantationBlood Reviews, Vol. 9, No. 4Production of Genetically Modified Epstein-Barr Virus-Specific Cytotoxic T Cells for Adoptive Transfer to Patients at High Risk of EBV-Associated Lymphoproliferative Disease COLTON A. SMITH, CATHERINE Y.C. NG, HELEN E. HESLOP, MARTHA S. HOLLADAY, STACYE RICHARDSON, E. VICTORIA TURNER, SUSAN K. LOFTIN, CONGFEN LI, MALCOLM K. BRENNER, and CLIONA M. ROONEY27 March 2009 | Journal of Hematotherapy, Vol. 4, No. 2T cell receptor repertoire of CD4+ and CD8+ T cell subsets in the allogeneic bone marrow transplant recipientCancer Immunology Immunotherapy, Vol. 41, No. 2The contribution of marker gene studies to hemopoietic stem cell therapies23 December 2008 | STEM CELLS, Vol. 13, No. 5Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferationThe Lancet, Vol. 345, No. 8941Donor T Cells to Treat EBV-Associated LymphomaNew England Journal of Medicine, Vol. 331, No. 10CD4+CD25+ Regulatory T Cells in Hematopoietic Stem Cell Transplantation Volume 5Issue 3Mar 1994 InformationCopyright 1994, Mary Ann Liebert, Inc.To cite this article:PRINCIPAL INVESTIGATORS Helen E. Heslop, Malcolm K. Brenner, Cliona Rooney, CO-INVESTIGATORS Robert A. Krance, W. Mark Roberts, Richard Rochester, Colton A. Smith, Victoria Turner, John Sixbey, Robert Moen, and James M. Boyett.Administration of Neomycin Resistance Gene Marked EBV Specific Cytotoxic T Lymphocytes to Recipients of Mismatched-Related or Phenotypically Similar Unrelated Donor Marrow Grafts. St. Jude Children's Research Hospital, Memphis, Tennesse.Human Gene Therapy.Mar 1994.381-397.http://doi.org/10.1089/hum.1994.5.3-381Published in Volume: 5 Issue 3: March 19, 2008PDF download